Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
AbbVie Inc

AbbVie Inc (ABBV)

Closed June 22 4:00PM
After Hours: 7:46PM


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
140.0028.6032.650.0030.6250.000.00 %00-
145.0023.7527.7028.0725.7250.000.00 %02-
150.0018.6521.6022.6020.1250.000.00 %035-
152.5016.1519.0017.2017.5750.000.00 %01-
155.0013.6516.4016.6915.0250.000.00 %029-
157.5011.1514.3513.9012.750.000.00 %02-
160.009.8011.6511.7310.725-1.07-8.36 %51476/21/2024
162.506.359.408.657.875-1.55-15.20 %1956/21/2024
165.005.706.505.786.10-2.08-26.46 %485156/21/2024
167.503.554.304.253.925-1.30-23.42 %18636/21/2024
170.001.802.062.341.93-0.92-28.22 %1487956/21/2024
172.500.750.880.820.815-1.02-55.43 %3585436/21/2024 %4701,2286/21/2024
177.500. %1043416/21/2024 %38466/21/2024
182.500. %355436/21/2024 %5216/21/2024
187.500. %00- %00-
192.500. %00-

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade %25526/21/2024 %018- %0105-
152.500. %00- %0190-
157.500. %1166/21/2024 %421986/21/2024
162.500. %34536/21/2024 %654226/21/2024
167.500.440.570.490.5050.0922.50 %321166/21/2024 %118976/21/2024
172.502.542.742.342.640.3517.59 %414666/21/2024
175.003.655.703.354.6750.000.00 %02-
177.505. %01-
180.007.459.957.858.700.000.00 %01-
182.509.7012.250.0010.9750.000.00 %00-
185.0012.2014.800.0013.500.000.00 %00-
187.5014.7017.950.0016.3250.000.00 %00-
190.0017.2019.9017.7318.55-11.43-39.20 %206/21/2024
192.5019.7022.700.0021.200.000.00 %00-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
AREBAmerican Rebel Holdings Inc
$ 0.76
SHCRSharecare Inc
$ 1.365
NXLNexalin Technologies Inc
$ 1.7499
$ 6.1209
SPECSpectaire Holdings Inc
$ 0.50
FLFVFeutune Light Acquisition Corporation
$ 2.5502
FLFVUFeutune Light Acquisition Corporation
$ 2.75
RWODRedwoods Acquisition Corporation
$ 2.34
KAVLKaival Brands Innovations Group Inc
$ 1.23
RWODURedwoods Acquisition Corporation
$ 3.24
NVDANVIDIA Corporation
$ 126.57
AREBAmerican Rebel Holdings Inc
$ 0.76
SIRISirius XM Holdings Inc
$ 2.94
AAPLApple Inc
$ 207.49
NKLANikola Corporation
$ 0.3466

ABBV Discussion

View Posts
mrfrederikson mrfrederikson 3 days ago
Cool! Thanks for the good news.
DewDiligence DewDiligence 4 days ago
FDA approves ABBV’s Skyrizi for first-line ulcerative colitis:
• Approval supported by two Phase 3 clinical trials that evaluated SKYRIZI for the treatment of moderate to severe ulcerative colitis: a 12-week induction study, INSPIRE,1 and a 52-week maintenance study, COMMAND

• Data showed that clinical remission, the primary endpoint in both the induction and maintenance studies, was achieved along with endoscopic improvement, a key secondary endpoint

• SKYRIZI is the first IL-23 antagonist approved for both ulcerative colitis and Crohn's disease ABBV’s Rinvoq, which is oral, is also approved in UC and Crohn’s disease following first-line treatment with a TNF-a agent such as Humira (#msg-171942039). Thus, Skyrizi and Rinvoq together give ABBV a bruising one-two punch in IBD, which accounts for about 40% of the overall market addressed by these agents (and Humira).

ABBV says Skyrizi and Rinvoq will have combined worldwide sales of $27B by 2027, several billion more than the peak annual sales attained by Humira.
👍️ 1
DewDiligence DewDiligence 7 days ago
Mini-tender offers are cropping up more often in drug/biotech industry:

For a stock like ABBV that has ample trading volume, it makes little sense for a shareholder to tender.
DewDiligence DewDiligence 2 months ago
ABBV 1Q24 CC transcript:
DewDiligence DewDiligence 2 months ago
ABBV reports 1Q24 results—raises 2024 guidance:

New 2024 non-GAAP EPS guidance $11.13-11.33, up from the prior guidance of $11.05-11.25 three months ago. The new guidance includes an ($0.08) hit from IPR&D occurring in 1Q24, which was not in the prior full-year 2024 guidance.

The midpoint of the new range ($11.23) represents 1% YoY growth from the actual $11.11 in 2023. The lack of robust YoY growth is due, in large part, to the continued uptake of Humira biosimilars in the US market.
Monksdream Monksdream 3 months ago
ABBV new 52 week hi
DewDiligence DewDiligence 4 months ago
ABBV inks drug-discovery collaboration with (private) Tentarix: AbbVie and Tentarix Biotherapeutics today announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology. The collaboration will integrate AbbVie's expertise in oncology and immunology with Tentarix's proprietary Tentacles™ platform.

Tentacles™ are multi-functional, conditionally-active antibody-based biologics that are designed specifically to activate immune cells that can modulate disease pathways, while potentially mitigating safety concerns associated with non-specific targeting of other immune cells. How are “tentacles” different from ADCs?
Monksdream Monksdream 5 months ago
ABBV new 52 week high
budgetthis budgetthis 5 months ago
Looking good, Abbvie!

Various Anslysts like us.

How nice. Let’s rock on this week.

$$ ABBV $$
DewDiligence DewDiligence 5 months ago
ABBV 4Q23 CC transcript:
DewDiligence DewDiligence 5 months ago
ABBV reports 4Q23 results—issues 2024 guidance:

2024 non-GAAP EPS guidance is $11.05-11.25, essentially flat relative to $11.11 in 2023. The lack of material YoY growth is due, in part, to the continued uptake of Humira biosimilars in the US market.
👍️ 1
Southern Gal Southern Gal 6 months ago
DewDiligence DewDiligence 8 months ago
ABBV 3Q23 CC transcript:
DewDiligence DewDiligence 8 months ago
ABBV reports 3Q23 results—raises_2023 non-GAAP EPS guidance:

The new 2023 non-GAAP EPS guidance is $11.19-11.23 (up from the prior range of $10.90-11.20). The sharp decline from 2022’s non-GAAP EPS of $13.77 is due to the launch of Humira biosimilars in the US market.
👍️ 1
DewDiligence DewDiligence 11 months ago
ABBV 2Q23 CC transcript:
DewDiligence DewDiligence 11 months ago
ABBV reports 2Q23 results—raises_2023 non-GAAP EPS guidance:

The new 2023 non-GAAP EPS guidance is $10.90-11.20 (up from the prior range of $10.57-19.97). The sharp decline from 2022’s non-GAAP EPS of $13.77 is due to the launch of Humira biosimilars in the US market. However, the uptake of Humira biosimilars in the US market has been somewhat slower than anticipated, which is the main reason for ABBV’s increasing its 2023 non-GAAP EPS guidance.

DewDiligence DewDiligence 1 year ago
ABBV’s $21B buyout of PCYC is_looking_worse_lately: Because of Imbruvica’s toxicity [see #msg-170086344], the National Comprehensive Cancer Network (NCCN) recently downgraded its guidance on Imbruvica, removing the AbbVie/J&J drug from a “preferred” regimen status. The NCCN guidelines committee has instead placed [BGNE’s] Brukinsa above Imbruvica in several areas.

…Facing double pressure from Brukinsa and AstraZeneca’s Calquence, Imbruvica has been on fast decline. First-quarter sales of the first-generation BTK inhibitor dropped 25% year on year to $878 million for AbbVie. The above article is about a new patent-infringement suit by ABBV against BGNE.

Note: The 2015 buyout of PCYC gave ABBV only half the worldwide commercial rights to Imbruvica (#msg-111425234).
DewDiligence DewDiligence 1 year ago
ABBV -3% on_announcement_of_low-priced Humira biosimilar from CHRS—including distribution by Mark’s Cuban’s CostPlus pharmacy:
DewDiligence DewDiligence 1 year ago
ABBV/GMAB—FDA approves Epkinly—(epcoritamab)—for r/rDLBCL:

Epkinly is a CD20-bispecific mAb. This is an accelerated approval based on a single-arm phase-2 trial.
DewDiligence DewDiligence 1 year ago
FDA approves Rinvoq for Crohn’s disease:

Rinvoq now has seven FDA–approved indications: RA; psoriatic arthritis; ankylosing spondylitis; axial spondyloarthritis; ulcerative colitis; and Crohn’s disease. In the five non-IBD indications (all except UC and Crohn’s), Rinvoq is indicated for second-line treatment following a TNF-a biologic.

ABBV now has three of the four IBD approvals it seeks: Rinvoq in UC and Crohn’s, and Skyrizi in Crohn’s. Based on phase-3 data (#msg-171517753), ABBV plans to submit a Skyrizi BLA for UC in 2023.

ABBV expects combined sales of Skyrizi and Rinvoq to teach $17.5B in 2025 and $21B in 2027 (#msg-170905881).
sunspotter sunspotter 1 year ago
Muddy Waters doesn't like the way Abbvie and Chinook have been presenting data on atrasentan:
DewDiligence DewDiligence 1 year ago
ABBV reports 1Q23 results—raises non-GAAP EPS guidance:

2023 non-GAAP EPS has been raised $0.10 at both the lower and upper bounds of the range, which is now $10.72-$11.12. This a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.
DewDiligence DewDiligence 1 year ago
ABBV—FDA expands Qulipta label_to prevention of chronic migraine:

Previously, Qulipta was approved for prevention of episodic migraine, but not chronic migraine. The distinction between the two indications is arbitrary but industry-standard. Chronic migraine is defined as a condition that causes >=15 headache days per month of which >=8 days are migraine.

ABBV’s migraine portfolio also includes Ubrelvy for treatment of acute migraine and Botox for prevention of chronic migraine.

Qulipta’s main competition is PFE’s Nurtec.
DewDiligence DewDiligence 1 year ago
Skyrizi phase-3 in UC hits all endpoints:

Skyrizi is currently approved in Crohn’s disease, but not in UC.
DewDiligence DewDiligence 1 year ago
ABBV advances Rinvoq to phase-3 in lupus:
DewDiligence DewDiligence 1 year ago
ABBV receives CRL for ABBV-951 due to FDA questions about the pump delivery device:
DewDiligence DewDiligence 1 year ago
ABBV 4Q22 CC transcript:
DewDiligence DewDiligence 1 year ago
ABBV pipeline update:
DewDiligence DewDiligence 1 year ago
ABBV reports 4Q22 results—issues 2023 guidance:

ABBV’s 2023 non-GAAP EPS guidance is $10.70-11.10, a sharp decline from 2022’s $13.77 due to the launch of Humira biosimilars in the US market.
DewDiligence DewDiligence 1 year ago
ABBV introduces Juvederm Volux—a_dermal_filler_for jawline augmentation:

This offering expands the Juvederm XC product line, which includes, in ascending order of heaviness: Volbella (for lips); Vollure (for nasolabial folds); Voluma (for mid-face augmentation), and Volux (for jawline).
DewDiligence DewDiligence 1 year ago
ABBV JPM slide set:
DewDiligence DewDiligence 1 year ago
ABBV now_expects Skyrizi/Rinvoq combined_2025_ sales_>=$17.5B—(up_from_prior_guidance_of_>=$15B):

ABBV also expects peak combined annual sales of these two drugs will exceed $21B in 2027.

All this despite the JAK limitation of Rinvoq to the second-line setting in most indications.
conix conix 1 year ago
ABBV in Investor's Daily
DewDiligence DewDiligence 2 years ago
ABBV’s neurotoxin, AGN-151607 misses primary endpoint in prevention of PAOF (PostOperative Atrial Fibrillation) in cardiac-surgery patients:

AGN-151607 is a Type-A botulinum toxin that, unlike Botox, is intended for cardiology indications.
DewDiligence DewDiligence 2 years ago
ABBV 3Q22 CC transcript:
DewDiligence DewDiligence 2 years ago
ABBV 3Q22 results:
trkyhntr trkyhntr 2 years ago
Why does ABBV show up as delisted?
DewDiligence DewDiligence 2 years ago
Impetus for ABBV selloff today: Imbruvica (ibrutinib): new risk minimisation measures, including dose modifications, due to the increased risk for serious cardiac events

This DHPC aims to inform healthcare professionals about an increased risk of fatal and serious cardiac arrhythmias and cardiac failure with the use of ibrutinib.

...Patients with advanced age, Eastern Cooperative Oncology Group (ECOG) performance status >-2, or cardiac co-morbidities may be at greater risk of cardiac events including sudden fatal cardiac events.

The PRAC advises that a clinical evaluation of cardiac history and function should be performed before starting a treatment with ibrutinib. In patients with risk factors for cardiac events, benefits and risks should be assessed before initiating treatment with the medicine and alternative treatment may be considered. Patients should be carefully monitored during treatment for signs of deterioration of cardiac function and be clinically managed.

Ibrutinib should be withheld for any new onset or worsening of grade 2 cardiac failure or grade 3 cardiac arrhythmias. Treatment may be resumed as per new dose modification recommendations.

The DHPC for Imbruvica will be forwarded to EMA’s human medicines committee (CHMP). Following the CHMP decision, the DHPC will be disseminated to healthcare professionals by the marketing authorisation holder, according to an agreed communication plan, and published on the ‘Direct healthcare professional communications’ page and in national registers in EU Member States.Emphasis added.
TechandBio TechandBio 2 years ago

Imbruvica (ibrutinib) Pharmacyclics (AbbVie)
2021 Sales $9,777,000,000.00

Data was excellent. Doubled CR of (ABBV) ibrutinib alone in MCL

Data in P53 mutant CCL is game changing

ABBV Let this sink in on how valuable this combo is $$$ for ABBV

Two ROR1 acquisitions Merck acquired early clinical data VelsoBio.. for $2.8 Billion & Boehringer buys NBE Therapeutics $1.5Billion ROR1 deal last year.

TechandBio TechandBio 2 years ago
Great informant video of ABBV & ONCT combos in the clinic (cancer stem cells)

TechandBio TechandBio 2 years ago
ABBV 2 trials one with ibrutinib & the other zilovertamab with Oncternal Therapeutics ROR1 molecule the data speaks for itself. This is going to be huge for ABBV bottom line.

ABBV with Oncternal Therapeutics Presents Updated Interim Data for Zilovertamab in Combination with Ibrutinib at ASCO 2022 Phase 3 starts in a few weeks in ths usa.
May 26, 2022 at 5:15 PM EDT

Updated MCL and CLL data from the CIRLL study are encouraging and continue to improve
ORR of 85% (23 of 27 evaluable patients) and CR rate of 41% (11 of 27 evaluable patients) for patients with MCL treated with zilovertamab plus ibrutinib compare favorably to historical ORR of 66% and CR of 20% for ibrutinib monotherapy
Data from p53-mutated MCL and CLL patients show encouraging response rates in sub-group analyses. Landmark PFS was over 80% at 15 months for MCL and 100% at 36 months for CLL in p53-mutated patients treated with zilovertamab plus ibrutinib
The combination of zilovertamab and ibrutinib continued to be well tolerated, with an adverse event profile consistent or improved compared with historical data for ibrutinib monotherapy.
ONCT is going to help ABBV with ibrutinib sales & with investigator-initiated studies, including a Phase 2 clinical trial of zilovertamab in combination with venetoclax, a Bcl-2 inhibitor, in patients with relapsed/refractory CLL, and in a Phase 1b study of zilovertamab in combination with docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC).
I think ABBV buys ONCT sooner than later 10 drugs in their pipeline.

ZILO-301: Phase III study of zilovertamab + ibrutinib vs ibrutinib in R/R MCL
(VIDEO 2 min)

DewDiligence DewDiligence 2 years ago
ABBV 2Q22 results:

2022 non-GAAP EPS guidance is unchanged at $13.78-13.98, including a $0.23 charge for in-process R&D during 1H22, but no IPR&D charge relating to 2H22 insofar as M&A activity during 1H22 is not yet known

ABBV set aside $2B to settle opioid litigation ( ), but this charge is excluded from the non-GAAP results are guidance.
DewDiligence DewDiligence 2 years ago
ABBV submits NDA/MAA for Rinvoq in Crohn’s disease:
DewDiligence DewDiligence 2 years ago
ABBV submits Qulipta sNDA for prevention of chronic migraine:

The FDA approved Qulipta for prevention of episodic migraine in Oct 2021 (#msg-166135709).
DewDiligence DewDiligence 2 years ago
FDA approves Skyrizi for Crohn’s disease:
DewDiligence DewDiligence 2 years ago
ABBV 1Q22 CC transcript:
retired early retired early 2 years ago
Didn't expect that. Bailed and wiped out most of last months ABBV flip gains. That's how it goes sometimes. :)
DewDiligence DewDiligence 2 years ago
ABBV 1Q22 results:

Non-GAAP EPS has been lowered by $0.08 due to a FASB accounting change re in-process R&D (i.e. accounting for acquisitions). The new range is $13.92-14.12.
retired early retired early 2 years ago
Or perhaps we are done correcting? :) Earning coming soon.
Just the facts maam Just the facts maam 2 years ago
Thanks DewDilligence, you are most likely right about Androgel, but I found it odd that they had a 48 month estimated completion for their trial though having 60 month time frame. At the very least the estimated completion date should have been June 2023. Though the time to Major Adverse Cardiac Event is the primary outcome and they are looking a cardiovascular a nd prostate cancer safety. The trial is also looking at other indications including: sexual activity, depression, bone fractures and anemia diabetes.

As for Libigel, there appears to be more to the story. As you stated it did fail to show efficacy for HSDD due to a large placebo effect. But the larger safety trial was also measuring efficacy and had a surgically menopausal population similar in size to the total of the two pivotal efficacy trials. They efficacy her was being measured in similar method used in the Intrinsa trials. The results form this trial have yet to be released. Secondary outcomes for this trial were never disclosed, as well.

It is true that ABBT/ABBV have never publicly owned or expressed an interest in female testosterone. However, I and a few others can attest to the fact that Dr. Michael Snabes' Linkedin profile, at one time, stated that he worked for AbbVie as early as January 2013 while working for Biosante at the same time. His linked in work history now reads as if there was no overlap, with him starting at AbbVie in April 2013.

Additionally up until, ATRS was issued a patent for using Testosterone to treat HSDD, ABBT was seeking a similar patent.

Dr. Snabes discovered that Libigel reduced Cardiovascular events over placebo ( never publicly disclosed). It appears that Libigel safety/efficacy trial or at least the observation of the 3,656 participants went beyond the December 2012 completion date. This became evident on December 19, 2015, when during the patent prosecution for reducing cardiovascular events (Dr. Snabes as inventor) they added the claim that restoring testosterone also reduced breast cancer events. In September 2012, the reduction in breast cancer events by restoring testosterone was not present. Interestingly, the support for the claim that it reduced cardiovascular events is well documented in the specifications of their patent application, but there is no such support for the breast cancer reduction claim. If ANIP had continued the work to make such a claim they would likely provided the supportive information to their claim in the specifications document accessible through the Public Pair. It also would have shown up in their R&D expenses as ANIP is a smaller company and it would be hard to hide the expenses related the follow-up of the participants.

According to the American Heart Journal article titled "A cardiovascular safety study of LibiGel (testosterone gel) in postmenopausal women with elevated cardiovascular risk and hypoactive sexual desire disorder" which also credits Dr Snabes.

Study procedures

There are 9 clinical visits and 14 telephone contacts during the course of the study (Figure 1). Office visits will occur at screening and randomization and at 3, 6, and 12 months postrandomization and yearly thereafter. Telephone contacts will be completed at week 6, month 9, and at 3-month intervals unless a clinical visit is required. Subjects are instructed to contact sites if they believe that they have experienced a CV event or breast cancer. At each scheduled contact, participants are asked about adverse events and health care and hospitalizations; questioned about specific androgenic side effects, potential CV events, and breast cancer; and undergo other assessments of safety and tolerability as well as laboratory measures.

Efficacy will be evaluated at office visits and telephone contacts using the Subject Global Assessment and Perception of Benefit Questions.Participants who discontinue study drug will be encouraged to complete all study visits, examinations, and questionnaires and to report potential CV events and breast cancer.

Breast and endometrial safety examinations

Breast examination and mammography will be performed at baseline and annually. Endometrial biopsy will be performed at baseline and at study years 1, 2, and 5. Participants with vaginal bleeding will undergo uterine evaluation that includes an endometrial biopsy. Study medication will be discontinued in participants with evidence of uterine cancer, complex or adenomatous hyperplasia, or atypia.
The 3,656 participant trial was an adaptive trial under an FDA Special Protocol Assessment set up in two parts, the first part being pre-commercialization. For which Biosante appears to have met.

ANIP has deflected or stopped responding to shareholder questions related to Libigel development since 2016. The full 5 year, 3,656 participant study would have been completed in August 2016. The Certification/Extension request to delay submission of results on October 27, 2021, is puzzling, unless an NDA has been filed or was about to be filed by a company other than ANIP. Logic dictates that if an NDA is being filed, AbbVie with Dr Snabes, would have been in the best position to take the first FDA approved female testosterone product across the finish line. Especially since AbbVie now owns the Intrinsa data.

Is Libigel's safety/efficacy data, supported by Intrinsa's trial data and the Global Consensus Position Statement on the Use of Testosterone Therapy for Women enough to support an approval?

The position statement issued in September 2019, provides guidelines in administering testosterone considered to be a benchmark. It provides clinical guidance regarding the use of testosterone therapy in women, examining the effect on sexual function; well-being, mood, and cognition; musculoskeletal effects; cardiovascular and breast health; as well side effects and adverse events. This is first time expert global agreement has been provided on how testosterone should be measured in women and how it should be therapeutically prescribed.

The Position Statement is largely based on the findings of the Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomized controlled trial data. The study reviewed 36 clinical trials (excluding all phase 3 LibiGel clinical trials), involving 8,480 participants in total. The Position Statement found that though no established indications for testosterone therapy for women existed, clinicians have been treating women with testosterone for decades, uncertain of the benefits and the risks. In most countries, including the United States, testosterone therapy is prescribed off-label male testosterone or compounded therapies. They also found that further investigation is warranted with respect to an individual's well-being, musculoskeletal and cognitive health and long-term safety. (LibiGel should address the long-term safety issue when the trial data is finally published.)

The Position Statement has been endorsed by the following organizations:

The International Menopause Society,
The Endocrine Society,
The European Menopause and Andropause Society,
The International Society for Sexual Medicine,
The International Society for the Study of Women's Sexual Health,
The North American Menopause Society,
The Federacion Latinoamericana de Sociedades de Climaterio y Menopausia,
The Royal College of Obstetricians and Gynaecologists,
The International Society of Endocrinology,
The Endocrine Society of Australia, and
The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.

According to the Position Statement, testosterone should only be used to treat HSDD after other options have not proved beneficial and testing shows that a women is testosterone deficient. It only recommends transdermal or cream applications. Where an appropriate approved female testosterone preparation is not available, off label, prescribing of an approved male formulation is considered reasonable. It does not recommend injectables, pellets or formulations that result in supraphysiological blood concentrations of testosterone, or compounded testosterone.

In the end AbbVie may not be interested in female testosterone. But they appear miles ahead of any competition should they want to enter a market with potentially no competition until December of 2033.

Your Recent History

Delayed Upgrade Clock